Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Bodybuilding Health+ vs RxSpan MD

Bodybuilding Health+
Graded #35

Lower grade

vs+10
RxSpan MD
Graded #10

Higher grade

The verdict

RxSpan MD takes it — 86/100 to 76/100.

RxSpan MD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. A physician-led telehealth under board-certified founder Dr. John Diaz with a broad GLP-1 menu — compounded semaglutide and tirzepatide by injection or oral capsule, plus a brand-name lane and microdosing — on transparent all-inclusive pricing to all 50 states.

Assume any provider we list may compensate us — we may earn a commission at no cost to you. It never changes the WeighScore.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueBodybuilding Health+ +2
88
86
Dose & formulationRxSpan MD +5
84
89
Clinical oversightRxSpan MD +14
74
88
Labs & monitoringRxSpan MD +15
68
83
FulfillmentRxSpan MD +11
78
89
Contract termsRxSpan MD +23
62
85
Bodybuilding Health+ · left barRxSpan MD · right bar

The numbers

MetricBodybuilding Health+RxSpan MD
WeighScore76/10086/100
GradeCB
Scorecard rank#35#10
SemaglutideFrom $139/moFrom $194/mo
TirzepatideFrom $139/mo$329/mo
CoverageNot disclosedAll 50 states
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyYes
Bodybuilding Health+

Graded #35 · C

Strengths

  • Low, publicly listed bundle pricing — compounded semaglutide and tirzepatide both fall to $139/mo on the 12-month plan (first month $179 sema / $209 tirz)
  • Licensed brand extension of Bodybuilding.com (trademark relationship stated on-site), which lends familiarity vs. anonymous GLP-1 startups
  • Unusually broad menu under one login — GLP-1 plus NAD+ (injection or nasal), sermorelin (injection or sublingual ODT), ED/tadalafil, and a deep peptide catalog
  • Standard telehealth flow with clear FDA/compounding disclaimers — online intake reviewed by independent licensed providers, U.S. compounding-pharmacy fulfillment, free until a provider approves

Where it loses points

  • Compounded and not FDA-approved — not Wegovy/Ozempic or Zepbound/Mounjaro; the site itself states these have not been evaluated by the FDA for safety, effectiveness, or quality
  • Brand-new operator — Dynamo Group LLC launched the storefront around April 2026 with only a thin, mixed ~26-review Trustpilot record (cancellation and billing complaints)
  • All sales final — prescription products are non-returnable, the medical-consult fee is non-refundable, and there are no refunds for dissatisfaction or results
  • Pharmacy and provider network aren't named on the live consumer pages, no LegitScript seal we could verify on-site, and the catalog reaches into investigational Retatrutide and research-grade peptides
RxSpan MD

Graded #10 · B

Strengths

  • Available in all 50 states
  • Transparent, all-inclusive published pricing — consult, medication, supplies, shipping and support, cancel anytime, from ~$194/mo compounded semaglutide on an annual plan
  • Both injectable and a real oral (capsule) route, plus compounded and an advertised brand-name lane
  • Physician-led by a named, board-certified founder (Dr. John Diaz) with 24/7 messaging and coaching

Where it loses points

  • Compounded semaglutide/tirzepatide are not FDA-approved (not the same as Wegovy/Ozempic/Zepbound)
  • Published pricing is for the compounded line — brand-name pricing isn’t itemized
  • A prescription isn’t guaranteed — a provider reviews eligibility after checkout

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 35 providers, CoreAge Rx grades highest at 94/100 (A). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard